AstraZeneca (AZN,AZN.L,ZEG.DE,AZN.ST) said Alexion, AstraZeneca Rare Disease's Koselugo has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The approval by Health Canada was based on positive results from KOMET.
Koselugo has been recently approved in the US, EU, Japan and other countries for the treatment of adult patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on data from the KOMET Phase III trial, and additional regulatory reviews are ongoing.
In pre-market trading on NYSE, AstraZeneca shares are down 2.78 percent to $188.92.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.